Quick Answer
Co-Diagnostics, Inc. reported Diluted EPS of $35.25 per share (loss) for fiscal year 2025.
Co-Diagnostics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$35.25 | +5.3% |
| 2024 | -$37.22 | -3001.7% |
| 2023 | -$1.20 | -166.7% |
| 2022 | -$0.45 | -136.6% |
| 2021 | $1.23 | -19.1% |
| 2020 | $1.52 | +510.8% |
| 2019 | -$0.37 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.16 | +50.0% | +30.4% |
| June 30, 2025 | -$0.23 | +8.0% | +4.2% |
| March 31, 2025 | -$0.24 | +22.6% | +25.0% |
| September 30, 2024 | -$0.32 | -60.0% | -28.0% |
| June 30, 2024 | -$0.25 | +19.4% | +19.4% |
| March 31, 2024 | -$0.31 | -55.0% | -55.0% |
| September 30, 2023 | -$0.20 | -400.0% | +35.5% |
| June 30, 2023 | -$0.31 | -287.5% | -55.0% |
- Co-Diagnostics, Inc. showed an increase of +5.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Co-Diagnostics, Inc.’s diluted eps has declined by 9427.0% (from $0.37 per share (loss) to $35.25 per share (loss)).
- The most recent figure is from Co-Diagnostics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: